切换至 "中华医学电子期刊资源库"

中华胸部外科电子杂志 ›› 2015, Vol. 02 ›› Issue (02) : 98 -104. doi: 10.3877/cma.j.issn.2095-8773.2015.02.005

所属专题: 文献

论著

非小细胞肺癌患者围术期内皮抑素和表皮生长因子受体水平对生存的影响
吴伟铭1, 何伟伟1, 高宗礼1, 赵天成1, 杨异1,()   
  1. 1. 200233 上海交通大学附属第六人民医院胸外科
  • 收稿日期:2014-11-16 出版日期:2015-05-28
  • 通信作者: 杨异
  • 基金资助:
    上海市卫生局科研计划资助项目(2009088)

Influence of endostain and epithelial growth factor receptor on the survival of the perioperative no-small cell lung cancer

Weiming Wu1, Weiwei He1, Zongli Gao1, Tiancheng Zhao1, Yi Yang1,()   

  1. 1. Deparment of Thoracic Surgery, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
  • Received:2014-11-16 Published:2015-05-28
  • Corresponding author: Yi Yang
  • About author:
    Corresponding author: Yang Yi, Email:
引用本文:

吴伟铭, 何伟伟, 高宗礼, 赵天成, 杨异. 非小细胞肺癌患者围术期内皮抑素和表皮生长因子受体水平对生存的影响[J/OL]. 中华胸部外科电子杂志, 2015, 02(02): 98-104.

Weiming Wu, Weiwei He, Zongli Gao, Tiancheng Zhao, Yi Yang. Influence of endostain and epithelial growth factor receptor on the survival of the perioperative no-small cell lung cancer[J/OL]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2015, 02(02): 98-104.

目的

分析非小细胞肺癌(NSCLC)患者的临床和病理特征、围术期血清内皮抑素和表皮生长因子受体(EGFR)水平对患者生存的影响。

方法

收集2008年1月至12月在上海交通大学附属第六人民医院胸外科接受手术治疗的50例NSCLC患者,从术后开始随访至2014年1月,平均随访时间为36.44个月。采用多因素回归分析方法分析50例NSCLC患者生存的相关因素。

结果

50例NSCLC患者的5年生存率为53.7%,中位生存期为50.6个月。肿瘤最大径<3.5 cm的患者生存率显著优于肿瘤最大径≥3.5 cm的患者(χ2=8.086,P=0.004);肺腺癌患者的生存率显著优于肺鳞癌患者(χ2=7.527,P=0.006);术后病理分期Ⅰ期的患者生存率显著优于Ⅱ和Ⅲ期患者(χ2=4.681,P=0.03;χ2=7.990,P=0.005);术前内皮抑素水平<20.4 ng/ml的患者生存率显著优于内皮抑素水平≥20.4 ng/ml的患者(χ2=5.213,P=0.022);术后EGFR水平≥44.7 pg/ml的患者生存率显著优于EGFR水平<44.7 pg/ml的患者(χ2=13.908,P=0.000),差异均有统计学意义。多因素回归分析显示术后EGFR水平是影响预后的独立因素(P=0.000)。

结论

术前内皮抑素水平低的患者和术后EGFR水平高的患者具有更好的生存优势。

Objective

To investigate the influence of clinicopathological characteristics, endostain and epithelial growth factor receptor(EGFR) on the survival of the perioperative non-small cell lung cancer(NSCLC).

Methods

Fifty patients with NSCLC undergoing surgical treatment in the Department of Cardiothoracic Surgery in Shanghai Sixth People’s Hospital affiliated to Shanghai Jiao Tong University between January 2008 and December 2008 were collected, and were followed up after surgery till January 2014, with the mean time of follow-up of 36.44 months. The survival-related factors for these 50 patients with NSCLC were analyzed using multivariate regression analysis.

Results

The 5-year survival was 53.7%, and the median survival time was 50.6 months for these 50 patients with NSCLC. The survival in patients with tumor maximum dimmer <3.5 cm was significantly bigger than that in those with tumor maximum dimmer ≥3.5 cm(χ2=8.086, P=0.004). The survival in patients with adenocarcinoma was significantly bigger than that in those with squamous carcinoma(χ2=7.527, P=0.006). The survival in patients with stage Ⅰ NSCLC was significantly bigger than those in patients with stage Ⅱ and stage Ⅲ NSCLC(χ2=4.681, P =0.03; χ2=7.990, P=0.005). The survival in patients with endostatin <20.4 ng/mL before operation was significantly bigger than that in those with endostatin≥20.4 ng/mL before operation(χ2=5.213, P=0.022). The survival in patients with EGFR ≥44.7 pg/mL after operation was significantly bigger than that in those with EGFR<44.7 pg/mL after operation (χ2=13.908, P=0.000). Multivariate regression analysis indicated that EGFR after operation was an independent prognostic factor(P=0.000).

Conclusion

The patients with low level of endostain before operation and high level of EGFR after operation may gain better survival.

表1 50例NSCLC患者的一般临床特征
表2 50例NSCLC患者围术期血液中内皮抑素和EGFR水平
图1 50例NSCLC患者的5年总体生存率
图2 不同病理类型对NSCLC患者生存期的影响
图3 肿瘤大小对NSCLC患者生存期的影响
图4 病理分期对NSCLC患者生存期的影响
图5 术前内皮抑素水平对NSCLC患者生存期的影响
图6 术后内皮抑素水平对NSCLC患者生存期的影响
图7 术前EGFR水平对NSCLC患者生存期的影响
图8 术后EGFR水平对NSCLC患者生存期的影响
表3 单因素分析NSCLC患者生存期的影响因素
[1]
Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis:role of the microenvironment[J]. Clin Exp Metastasis, 2009,26(1):51-60.
[2]
Zhao H, Huang Y, Xue C, et al. Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. [J]. PLoS One, 2013,8(1): e54674
[3]
Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Cell Res, 2006, 312(2):594-607.
[4]
Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models [J]. PLoS One, 2013, 8(6): e65757.
[5]
Hu MM, Hu Y, Zhang HQ, et al. Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer[J. Biomed Rep,2014,2(6): 898-904.
[6]
杨异,高宗礼,赵天成,等.手术对非小细胞肺癌患者血清中血管内皮生长因子受体2和内皮抑素水平的影响[J]. 肿瘤,2010,30(6):536-538.
[7]
Tanaka T, Konno H, Baba S, et a1. Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor fr-118487 after removal of growing tumor in mice[J]. Jpn J Cancer Res, 2001,92(1):88-94.
[8]
Kathy G, Lydia F, Sinead C, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer[J].Clin Lung Cancer,2014,15(1):58-66.
[9]
D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib[J]. J Thorac Oncol,2012,7(12):1815-1822.
[10]
Izar B, Sequist L, Lee M, et al. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers[J].Ann Thorac Surg,2013,96(3):962-968.
[11]
Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2) [J].J Thorac Oncol, 2012,7(10):1490-1502.
[12]
李新举,张伟,袁育康. 非小细胞肺癌血清及癌组织中EGFR蛋白定量检测[J].第四军医大学学报,2008,29(14):1303-1305.
[13]
Akca H, Demiray A, Yaren A, et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small celll lung cancer[J]. Cancer Genet,2013,206(3):73-80.
[14]
Kim ST, Jung HY, Sung JS, et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? [J] Am J Clin Oncol, 2013,36(1):57-63.
[15]
Li XF, Ren RX, Ren SX, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients[J].Transl Oncol, 2014,7(3):341-348.
[16]
Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J].J Thorac Oncol, 2012,7(1):115-121.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[6] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[7] 刘先勇, 秦东梅, 张若梅, 李俊娇, 孟春芹, 邬明歆, 王玉红, 赵新鲜, 徐瑞联, 洪文文, 马玲, 仇玮, 周宇. Her2/Hes1在肠型胃癌Correa级联反应3个病理阶段中的表达及意义[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 321-327.
[8] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[9] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[10] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要